Cargando…

Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience

The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Fermont, Irene R., Livneh, Ayalah, Benhamou, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358549/
https://www.ncbi.nlm.nih.gov/pubmed/35958047
http://dx.doi.org/10.1177/20420986221112189
_version_ 1784763956261289984
author Fermont, Irene R.
Livneh, Ayalah
Benhamou, Michel
author_facet Fermont, Irene R.
Livneh, Ayalah
Benhamou, Michel
author_sort Fermont, Irene R.
collection PubMed
description The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics. The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides evidence-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts’ meetings in Israel and abroad. Current resources: 40 webinars, all recorded and accessible on the association website, questions and answers, press and scientific literature review, and hotline; communication through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees’ number (~3000), website frequentation (7200 +) social media followers. In conclusion, this information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships. PLAIN LANGUAGE SUMMARY: Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience Background: The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics. An Israelian initiative: method: The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides science-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts’ meetings in Israel and abroad. Results: Current resources: More than 40 webinars, recorded, questions and answers, press and scientific literature review, and hotline, through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees number (~3000), website frequentation (7200 +) social media followers. In conclusion: This information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships.
format Online
Article
Text
id pubmed-9358549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-93585492022-08-10 Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience Fermont, Irene R. Livneh, Ayalah Benhamou, Michel Ther Adv Drug Saf Self-Medication and Pharmacovigilance in the Era of Infodemic The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics. The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides evidence-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts’ meetings in Israel and abroad. Current resources: 40 webinars, all recorded and accessible on the association website, questions and answers, press and scientific literature review, and hotline; communication through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees’ number (~3000), website frequentation (7200 +) social media followers. In conclusion, this information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships. PLAIN LANGUAGE SUMMARY: Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience Background: The scientific communication landscape has undergone a significant disruption since the COVID-19 pandemic: a huge number of publications, ample use of preprint publications, a fast-spreading digitalized information. This reflected the unprecedented speed of the research on disease and vaccines. Two kinds of infodemic blew up very soon: a scientific and a tabloid one. With knowledge evolving continuously, governments and institutions deployed their communication campaigns very quickly to explain the different measures, including the vaccination strategies and to fight against infodemics. An Israelian initiative: method: The need for a more focused population, the French-speaking community, arose spontaneously in Israel, leading to the creation of a Vaccine Task Force, independent, multidisciplinary, and composed of 20 high-level volunteers, physicians, pharmacists, and scientists, which provides science-based information, open and free, to healthcare professionals and the public, both most in demand, and then the experts’ meetings in Israel and abroad. Results: Current resources: More than 40 webinars, recorded, questions and answers, press and scientific literature review, and hotline, through the website, social media, and audio-visual media. In French, English, and Hebrew. The team undertook to explain the role of Israel in vaccine rollout and real-world data provision to the international community, both in Israel and abroad. Performance indicators are as follow: attendees number (~3000), website frequentation (7200 +) social media followers. In conclusion: This information campaign requires no budget; relies on volunteers who expressed their willingness to contribute to the global effort, as seen all over the world; and uses simple, cheap, and ubiquitous IT platforms. The Task Force created ERANIM, the Israel Society for Medication and Vaccines Safety. This scheme could easily apply for minorities or for medium/low-income countries, using the resources available in WHO, Vaccine Safety Net, health agencies, and academies. Key factors are multidisciplinary, influencers belonging to communities, and a network of partnerships. SAGE Publications 2022-08-05 /pmc/articles/PMC9358549/ /pubmed/35958047 http://dx.doi.org/10.1177/20420986221112189 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Self-Medication and Pharmacovigilance in the Era of Infodemic
Fermont, Irene R.
Livneh, Ayalah
Benhamou, Michel
Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title_full Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title_fullStr Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title_full_unstemmed Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title_short Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
title_sort risk communication on vaccines during the covid19 pandemic: is there room for small size or private initiatives? an israeli experience
topic Self-Medication and Pharmacovigilance in the Era of Infodemic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358549/
https://www.ncbi.nlm.nih.gov/pubmed/35958047
http://dx.doi.org/10.1177/20420986221112189
work_keys_str_mv AT fermontirener riskcommunicationonvaccinesduringthecovid19pandemicisthereroomforsmallsizeorprivateinitiativesanisraeliexperience
AT livnehayalah riskcommunicationonvaccinesduringthecovid19pandemicisthereroomforsmallsizeorprivateinitiativesanisraeliexperience
AT benhamoumichel riskcommunicationonvaccinesduringthecovid19pandemicisthereroomforsmallsizeorprivateinitiativesanisraeliexperience